In contrast, patients with acquired mutations in CSF3R present very often with MDS/AML, therefore yearly screening for receptor mutations is indicated, as is pre-emptive alloHSCT (Table 2) (43). The gene discussed is CSF3R; the disease is myelodysplastic syndrome.